

Grifols Welcomes Moody's Ratings' Upgrade to B1 with Stable Outlook

- *Moody's Ratings has upgraded to B1 from B2 the corporate family rating (CFR), reflecting Grifols' continued strong operating performance*
- *Moody's has upgraded to B1-PD from B2-PD the probability of default rating (PDR) of Grifols, to Ba3 from B1 the instrument ratings of the backed senior secured instruments and to B3 from Caa1 the instrument ratings of the backed senior unsecured instruments*

Barcelona, Spain, February 16, 2026 – Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, welcomes Moody's decision to upgrade to B1 from B2 the corporate family rating (CFR) with a stable outlook, reflecting Grifols' continued operating performance and strong business characteristics.

Moody's B1 rating also reflects the company's strong market position, scale and vertical integration in human blood plasma-derived products, which are relevant for the industry, the favourable fundamental demand drivers of the sector, the high barriers to entry in the industry because of regulation, customer loyalty, and its good product safety track record. The rating also takes into consideration the company's current leverage, capital intensity of the business and working capital requirements.

Additionally, Moody's also decided to upgrade to B1-PD from B2-PD the probability of default rating (PDR) of Grifols. Consequently, Moody's has also upgraded to Ba3 from B1 the instrument ratings of the backed senior secured instruments issued by the company. At the same time, Moody's has upgraded to B3 from Caa1 the instrument ratings of the backed senior unsecured instruments issued by Grifols.

Moody's also changed the outlook on the company to stable from positive. The stable outlook reflects Moody's expectations that Grifols will continue to have a strong operating performance and prudent financial management over the next 12-18 months.

Rahul Srinivasan, Chief Financial Officer of Grifols, said: "We welcome Moody's validation of Grifols ongoing execution, deleveraging and free cashflow improvement progress, that remain key priorities for the company."

Grifols remains firmly committed to operational excellence, innovation in plasma-derived therapies, and financial discipline, foundations that underpin its long-term commitment to patient health, sustainable growth, and value creation.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel: +34 93 571 00 02



INVESTORS:

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.